文献速递流行病学与生物统计真实世界研究与卫生经济

摩尔多瓦6个月BPaLM方案治疗耐利福平结核的影响与成本效益:一项数学建模分析

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
PubMed 文献 · PLoS Med · 2024-05-03

该数学建模分析比较了6个月BPaLM方案与根据氟喹诺酮耐药检测结果选用9或18个月方案的标准治疗策略,针对摩尔多瓦15岁及以上耐利福平肺结核患者。结果显示6个月BPaLM具有成本效益,每例终生成本降低3366美元(95% UI:1465至5742,p<0.001),QALYs变化无统计学意义(-0.06;

要点

  • 6个月BPaLM方案较标准治疗每例终生成本降低3366美元(95% UI:1465至5742,p<0.001),QALYs无显著变化。
  • 若停用莫西沙星后继续BPaL联合氯法齐明(BPaLC),可获得更多QALYs且成本低于单用BPaL。

核心结论

  • 与标准治疗即较长方案相比,实施6个月BPaLM方案可提高耐利福平结核患者治疗的成本效益,尤其在耐药结核负担高的地区。
  • 可能需要进一步研究以探讨更短耐利福平结核方案在不同耐药负担和国家收入水平地区的 impact 与成本效益。

研究设计与样本

  • 数学建模分析,使用基因组和人口学数据参数化模型,模拟摩尔多瓦15岁及以上被诊断为肺结核且耐利福平患者的长期健康结局(QALYs)和终生成本(2022年美元)。
  • 比较6个月BPaLM方案与根据药敏试验是否检出氟喹诺酮耐药而选用9或18个月方案的标准治疗策略。
  • 对每个个体模拟结核自然史、相关治疗结局以及针对12种抗结核药物获得耐药的过程。

主要发现

  • 与标准治疗相比,6个月BPaLM方案每例终生成本降低3366美元(95% UI:1465至5742,p<0.001),QALYs变化无统计学意义(-0.06;95% UI:-0.49至0.03,p=0.790)。
  • 在BPaLM方案中停用莫西沙星者,继续BPaL联合氯法齐明(BPaLC)较继续单用BPaL提供更多QALYs且成本更低。
  • 只要停用莫西沙星时继续BPaLC,基于6个月BPaLM的策略具有至少93%的概率具有成本效益。
  • 6个月BPaLM减少了耐阿米卡星、贝达喹啉、氯法齐明、环丝氨酸、莫西沙星和吡嗪酰胺结核的平均时间,但增加了耐德拉马尼和普托马尼结核的平均时间。

关键数值与推荐

  • 6个月BPaLM方案每例终生成本降低3366美元(95% UI:1465至5742,p<0.001)。
  • QALYs变化为-0.06(95% UI:-0.49至0.03,p=0.790),无统计学意义。
  • 基于6个月BPaLM的策略具有至少93%的概率具有成本效益,条件是在停用莫西沙星时继续BPaLC。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 分析未考虑特定药物之间在治疗结局、耐药获得或特定类型严重不良事件后果方面所有可能的交互作用。
  • 未建模该干预可能如何影响结核传播动力学。
  • 原文结论指出可能需要进一步研究以探讨更短耐利福平结核方案在不同耐药负担和国家收入水平地区的 impact 与成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST). METHODS AND FINDINGS: The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. This strategy was estimated to reduce lifetime costs by $3,366 (95% UI: [1,465, 5,742] p < 0.001) per individual, with a nonsignificant change in QALYs (-0.06; 95% UI: [-0.49, 0.03] p = 0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. Strategies based on 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. BPaLM for 6 months also reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p = 0.002) over the 5-year period from implementation. Our analysis did not account for all possible interactions between specific drugs with regard to treatment outcomes, resistance acquisition, or the consequences of specific types of severe adverse events, nor did we model how the intervention may affect TB transmission dynamics. CONCLUSIONS: Compared to standard of care, longer regimens, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings with a high burden of drug-resistant TB. Further research may be warranted to explore the impact and cost-effectiveness of shorter RR-TB regimens across settings with varied drug-resistant TB burdens and national income levels.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. James LP, Klaassen F, Sweeney S, et al. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLoS Med. 2024. PMID: 38701084. doi:10.1371/journal.pmed.1004401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。